Madrigal Pharmaceuticals, Inc. MDGL Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $311.34M-3.0% | $321.08M+11.8% | $287.27M+35.0% | $212.8M+55.0% | $137.25M+32.8% | ||
| —— | —— | —— | —— | —— | ||
| $108.69M-6.5% | $116.27M-33.2% | $174M+222% | $54.08M+22.4% | $44.17M+72.2% | ||
| $268.52M+11.9% | $239.98M+14.8% | $209.12M+6.2% | $196.86M+17.3% | $167.88M+18.9% | ||
| $404.06M+6.1% | $380.69M-5.1% | $401.24M+54.3% | $260M+20.1% | $216.56M+27.2% | ||
| $26.85M+9.8% | $24.45M+34.9% | $18.12M+99.9% | $9.07M+101% | $4.51M-99.3% | ||
| -$92.72M-55.6% | -$59.61M+47.7% | -$113.98M-141% | -$47.2M+40.5% | -$79.31M-18.4% | ||
| -29.8%-11.2pp | -18.6%+21.1pp | -39.7%-17.5pp | -22.2%+35.6pp | -57.8%+7.1pp | ||
| $7.82M-5.8% | $8.3M+11.4% | $7.45M+128% | $3.26M-1.0% | $3.3M-5.8% | ||
| -$2.09M-1,534% | -$128K+56.3% | -$293K-598% | -$42K— | $0— | ||
| -$94.39M-61.1% | -$58.58M+48.7% | -$114.19M-170% | -$42.28M+42.3% | -$73.24M-23.3% | ||
| -30.3%-12.1pp | -18.2%+21.5pp | -39.8%-19.9pp | -19.9%+33.5pp | -53.4%+4.1pp | ||
| -$3.25-60.1% | -$2.03+49.4% | -$4.01-167% | -$1.50+42.5% | -$2.61— | ||
| -$92.34M-55.9% | -$59.22M+47.9% | -$113.62M-143% | -$46.83M+40.7% | -$78.93M-18.5% | ||
| -29.7%-11.2pp | -18.4%+21.1pp | -39.6%-17.5pp | -22%+35.5pp | -57.5%+7.0pp | ||
| -$92.72M-55.6% | -$59.61M+47.7% | -$113.98M-141% | -$47.2M+40.5% | -$79.31M-18.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s revenue?
- Madrigal Pharmaceuticals, Inc. (MDGL) generated $1.1B in revenue over the trailing twelve months, up 256.8% year over year.
- Is Madrigal Pharmaceuticals, Inc. profitable?
- Madrigal Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $309.4M over the trailing twelve months, a -27.3% net margin.
- What are Madrigal Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 96.5% and operating margin is -27.7%, with a -27.3% net margin.
- What is Madrigal Pharmaceuticals, Inc.'s earnings per share?
- Madrigal Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-10.79.
- Where does Madrigal Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
